{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:00:14Z","timestamp":1758816014698,"version":"3.40.5"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>Ravulizumab is an expensive complement C5\u2010inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria. Recently, a subcutaneous formulation has entered the market, for which the approved dosing regimen results in supratherapeutic ravulizumab concentrations in the majority of patients in the registration studies. Therefore, we explored alternative dosing regimens in silico based on the registration data of the manufacturer. Extending the interval from 1 to 2\u2009weeks or individualized dosing based on therapeutic drug monitoring resulted in therapeutic ravulizumab concentrations and comparable predicted efficacy in terms of lactate dehydrogenase normalization, with dose reductions up to 64%. We here show that with an individualized dose, a substantial dose reduction for subcutaneous ravulizumab might be possible with improved patient\u2010friendliness.<\/jats:p>","DOI":"10.1111\/bcp.15602","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T06:55:19Z","timestamp":1668668119000},"page":"1211-1215","source":"Crossref","is-referenced-by-count":3,"title":["Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-4919","authenticated-orcid":false,"given":"Mendy","family":"ter Avest","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Health Sciences Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia M. C.","family":"Langemeijer","sequence":"additional","affiliation":[{"name":"Department of Haematology Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[{"name":"Department of Haematology Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[{"name":"Deparment of Paediatric Nephrology Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8201","authenticated-orcid":false,"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Health Sciences Radboud University Medical Centre  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,12]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Full Prescribing Information Ravulizumab.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s021lbl.pdf"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12347"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13783"},{"issue":"1","key":"e_1_2_9_5_1","first-page":"15","article-title":"Orphan drug pricing and payer management in the United States: are we approaching the tipping point?","volume":"3","author":"Hyde R","year":"2010","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_9_6_1","unstructured":"Reuters.FDA approves Alexion's Ultomiris for another rare blood disease. In 2019."},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","unstructured":"SahelijoL MujeebuddinA MitchellD et al.First in human single\u2010ascending dose study: safety biomarker pharmacokinetics and exposure\u2010response relationships of ALXN1210 a humanized monoclonal antibody to C5 with marked half\u2010life extension and potential for significantly longer dosing intervals. In: American Society of Hematology Washington DC 2015.","DOI":"10.1182\/blood.V126.23.4777.4777"},{"key":"e_1_2_9_8_1","unstructured":"BLA Multi\u2010Disciplinary Review and Evaluation BLA 761108 \u2010 Ultomiris (ravulizumab). In 2018."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14748"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112944"},{"key":"e_1_2_9_11_1","unstructured":"Ultomiris assessment report EMA\/CHMP\/220699\/2019. In 2019."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29095"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201009\u2010876136"},{"key":"e_1_2_9_14_1","unstructured":"A phase 3 randomized parallel\u2010group multicenter open\u2010label pharmacokinetic noninferiority study of ravulizumab administered subcutaneously versus intravenously in adult patients with paroxysmal nocturnal hemoglobinuria currently treated with eculizumab.https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002370-39\/ES"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11531280\u2010000000000\u201000000"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.2.19387"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15602","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15602","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T11:38:18Z","timestamp":1692272298000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/bcp.15602"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15602","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}